Genmab to acquire Merus for $8 billion

Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio

Novartis to launch DTP platform for Cosentyx in US

Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers

FDA grants De Novo classification to first needle-free, glucose sensor Biolinq Shine

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%

AbbVie begins construction of $70 million biologics manufacturing site in US

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology

DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future

India currently hosts more than 10,075 biotech startups

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine

Biocon Biologics secures US market entry date for Bosaya and Aukelso, Denosumab biosimilars

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment